For a deeper dive into the topic, refer to the GLP1 Medication overview
Clinical trials show no evidence of lasting metabolic damageyour resting energy expenditure and calorie-burning capacity return to your baseline metabolic rate, not a suppressed state
No Phase 3 efficacy trials have been completed for either form
GLP-1 RAs promote satiety, reduce hunger, and dampen reward responsivity, which conceptually could open a temporary low-drive window during which behavioral techniques such as stimulus control, self-monitoring, and structured eating routines become more achievable
Screening should also evaluate potential atypical anorexia nervosa symptoms, such as weight suppression (difference between maximum and current weight), fear of weight gain, starvation symptoms, and preoccupation with food
use within 12 weeks